Page last updated: 2024-12-11
mulberroside a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
mulberroside A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6443484 |
| CHEMBL ID | 455619 |
| CHEBI ID | 177974 |
| SCHEMBL ID | 22498775 |
| MeSH ID | M0379477 |
Synonyms (29)
| Synonym |
|---|
| 102841-42-9 |
| (2s,3r,4s,5s,6r)-2-[3-hydroxy-4-[(e)-2-[3-hydroxy-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol |
| CHEBI:177974 |
| mulberroside a |
| CHEMBL455619 |
| S9075 |
| n1520 , |
| unii-oju5sva08b |
| oju5sva08b , |
| CS-4679 |
| [2,5'-dihydroxy-4,3'-bis(beta-d-glucopyranosyloxy)-trans-stilbene] |
| AC-34709 |
| Q-100952 |
| mulberroside-a |
| HY-N0619 |
| AKOS030526209 |
| 3-((1e)-2-(4-(.beta.-d-glucopyranosyloxy)-2-hydroxyphenyl)ethenyl)-5-hydroxyphenyl .beta.-d-glucopyranoside |
| .beta.-d-glucopyranoside, 3-((1e)-2-(4-(.beta.-d-glucopyranosyloxy)-2-hydroxyphenyl)ethenyl)-5-hydroxyphenyl |
| mfcd16294844 |
| (2s,3r,4s,5s,6r)-2-(3-hydroxy-4-((e)-3-hydroxy-5-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)styryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol |
| Q6933784 |
| CCG-270083 |
| AS-56590 |
| SCHEMBL22498775 |
| bdbm50529592 |
| A904166 |
| 3-{(e)-2-[4-(beta-d-glucopyranosyloxy)-2-hydroxyphenyl]ethenyl}-5-hydroxyphenyl beta-d-glucopyranoside |
| DTXSID901030445 |
| mulberrosidea |
Research Excerpts
Overview
Mulberroside A is a natural polyhydroxylated stilbene compound present at relatively high abundance in the roots and twigs of Morus alba L. It is a glycosylate of oxyresveratrol. deglycosylation of mulberro side A resulted in enhanced inhibition of melanogenesis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Mulberroside A is a natural polyhydroxylated stilbene compound present at relatively high abundance in the roots and twigs of Morus alba L. " | ( Mulberroside A protects against ischemic impairment in primary culture of rat cortical neurons after oxygen-glucose deprivation followed by reperfusion. Ding, F; Li, GC; Li, JL; Liang, XM; Shi, YW; Wang, CP; Wang, ZW; Zhang, LZ; Zhang, XC, 2014) | 3.29 |
| "Mulberroside A is a major stilbene glycoside of MORUS ALBA L. " | ( Mulberroside a possesses potent uricosuric and nephroprotective effects in hyperuricemic mice. Hu, LS; Kong, LD; Wang, CP; Wang, X; Wang, Y; Ye, JF; Zhang, X, 2011) | 3.25 |
| "Mulberroside A is a glycosylated stilbene of oxyresveratrol; thus, the deglycosylation of mulberroside A resulted in enhanced inhibition of melanogenesis." | ( Inhibitory effect of mulberroside A and its derivatives on melanogenesis induced by ultraviolet B irradiation. Hwang, D; Kim, JK; Lim, YH; Park, KT; Yoo, Y, 2011) | 1.41 |
Actions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Mulberroside A was found to inhibit hippocampal neuroinflammation and neurogenesis reduction in HFrD-fed mice." | ( Mulberroside A repairs high fructose diet-induced damage of intestinal epithelial and blood-brain barriers in mice: A potential for preventing hippocampal neuroinflammatory injury. Kong, L; Li, J; Wang, C; Wang, Q; Wen, S; Wu, X; Yu, R; Zhang, L, 2021) | 2.79 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " This study examined the determining factors for previously reported oral pharmacokinetic profiles of MulA and its bacterial metabolite oxyresveratrol (OXY) on in vitro models." | ( In vitro pharmacokinetic characterization of mulberroside A, the main polyhydroxylated stilbene in mulberry (Morus alba L.), and its bacterial metabolite oxyresveratrol in traditional oral use. Lei, JP; Mei, M; Ruan, JQ; Wang, YT; Wu, WJ; Yan, R; Zhao, HY; Zhou, RN, 2012) | 0.64 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Potassium oxonate-induced hyperuricemic mice were dosed by gavage with eight stilbenes." | ( Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice. Hong, Y; Kong, LD; Li, Z; Liu, L; Liu, YL; Shi, YW; Wang, CP; Wang, X, 2012) | 0.38 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| glycoside | A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. |
| stilbenoid | Any olefinic compound characterised by a 1,2-diphenylethylene backbone. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tyrosinase | Mus musculus (house mouse) | IC50 (µMol) | 100.0000 | 0.0300 | 2.2104 | 5.2300 | AID1611935 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID332856 | Inhibition of 12-hydroxy-5,8,10-heptadecatrienoic acid formation in Wistar King platelets | |||
| AID332852 | Inhibition of 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in Wistar King platelets | |||
| AID1611935 | Inhibition of tyrosinase in mouse B16 cells | 2018 | Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17 | Inhibitors of Melanogenesis: An Updated Review. |
| AID332858 | Inhibition of thromboxane B2 formation in Wistar King platelets | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (27)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (11.11) | 29.6817 |
| 2010's | 22 (81.48) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 26.65
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.65) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (3.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 29 (96.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||